p38 MAP kinase inhibitors (Allinky)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namep38 MAP kinase inhibitors (Allinky)
Drug Alias NameAIK-1bAIK-a1AIK-1aAIK-1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsInflammationDiabetes Mellitus, Type 2Psoriasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAllinky Biopharma SL
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllinky Biopharma SL
Active IndicationsN/A
Inactive IndicationsInflammationDiabetes Mellitus, Type 2Psoriasis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A